Arcutis Biotherapeutics
ARQT
230 hedge funds and large institutions have $1.78B invested in Arcutis Biotherapeutics in 2025 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 89 increasing their positions, 66 reducing their positions, and 45 closing their positions.
216% more call options, than puts
Call options by funds: $10.3M | Put options by funds: $3.24M
35% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 66
0.67% more ownership
Funds ownership: 105.95% → 106.62% (+0.67%)
5% less funds holding
Funds holding: 241 → 230 (-11)
9% less capital invested
Capital invested by funds: $1.97B → $1.78B (-$184M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
22% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 45
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$31M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$15.3M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$12.9M |
| 4 |
Goldman Sachs
New York
|
+$11M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$9.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$23.8M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$22.9M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$17.2M |
| 4 |
CM
Cercano Management
Bellevue,
Washington
|
-$14.5M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$7.07M |
ARQT Hedge Fund Activity: Q2 2025 in Review
230 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q2 2025, worth a combined $1.78B — down 9.4% from $1.97B a quarter earlier.
Sellers outnumbered buyers: 45 funds closed out of ARQT and 35 opened new positions — a net loss of 10 holders — while 66 trimmed existing stakes and 89 added.
The largest buyer was Janus Henderson Group, adding an estimated $31M. The largest seller was Polar Capital Holdings, cutting an estimated $23.8M.
- 230 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q2 2025, down from 241 in Q1 2025.
- Funds reported $1.78B of Arcutis Biotherapeutics stock for Q2 2025, down 9.4% quarter-over-quarter.
- 35 funds opened new Arcutis Biotherapeutics positions in Q2 2025 and 45 closed out, a net change of -10 holders.
- The largest Arcutis Biotherapeutics buyer in Q2 2025 was Janus Henderson Group, an estimated $31M added.
- The largest Arcutis Biotherapeutics seller in Q2 2025 was Polar Capital Holdings, an estimated $23.8M sold.
Based on aggregated 13F filings for Q2 2025.